Privium Fund Management B.V. Grows Stock Position in Urogen Pharma (NASDAQ:URGN)

Key Points

• Privium Fund Management B.V. significantly increased its stake in Urogen Pharma by 288.7%, owning 107,622 shares valued at approximately $1.19 million.
• Multiple hedge funds, including CWM LLC and GAMMA Investing LLC, also dramatically boosted their holdings, reflecting growing institutional interest in Urogen Pharma, which now has 91.29% institutional ownership.
• Equities research analysts have a positive outlook on Urogen Pharma, with a consensus rating of "Buy" and target prices ranging from $16.00 to $31.00 per share.

Privium Fund Management B.V. grew its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 288.7% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 107,622 shares of the company's stock after buying an additional 79,931 shares during the quarter. Privium Fund Management B.V. owned approximately 0.23% of Urogen Pharma worth $1,190,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Renaissance Technologies LLC bought a new stake in shares of Urogen Pharma in the fourth quarter worth $1,472,000. Lazard Asset Management LLC bought a new stake in Urogen Pharma during the fourth quarter valued at about $67,000. Janus Henderson Group PLC bought a new stake in Urogen Pharma during the fourth quarter valued at about $149,000. ProShare Advisors LLC bought a new stake in Urogen Pharma during the fourth quarter valued at about $137,000. Finally, Rhumbline Advisers grew its holdings in Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after purchasing an additional 2,196 shares during the period. Hedge funds and other institutional investors own 91.29% of the company's stock.

Analyst Upgrades and Downgrades

URGN has been the topic of several research analyst reports. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. Guggenheim restated a "buy" rating and issued a $30.00 price objective (up from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th. Finally, The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $32.86.

Urogen Pharma Stock Down 6.6%

NASDAQ:URGN traded down $1.37 during midday trading on Wednesday, hitting $19.35. The stock had a trading volume of 594,638 shares, compared to its average volume of 1,588,789. Urogen Pharma has a one year low of $3.42 and a one year high of $21.01. The company has a market capitalization of $894.11 million, a price-to-earnings ratio of -6.08 and a beta of 1.12. The stock has a 50-day moving average of $13.17 and a 200 day moving average of $11.17.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. On average, sell-side analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. This trade represents a 15.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Schoenberg sold 5,149 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $98,551.86. Following the completion of the sale, the insider directly owned 158,229 shares of the company's stock, valued at $3,028,503.06. The trade was a 3.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,833 shares of company stock valued at $280,567 in the last three months. Insiders own 4.70% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.